Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Long-Term Deferred Tax (2020 - 2025)

Catalyst Pharmaceuticals' Long-Term Deferred Tax history spans 10 years, with the latest figure at $52.8 million for Q4 2025.

  • For Q4 2025, Long-Term Deferred Tax rose 14.76% year-over-year to $52.8 million; the TTM value through Dec 2025 reached $52.8 million, up 14.76%, while the annual FY2025 figure was $52.8 million, 14.76% up from the prior year.
  • Long-Term Deferred Tax reached $52.8 million in Q4 2025 per CPRX's latest filing, up from $48.3 million in the prior quarter.
  • In the past five years, Long-Term Deferred Tax ranged from a high of $52.8 million in Q4 2025 to a low of $18.7 million in Q4 2022.
  • Average Long-Term Deferred Tax over 5 years is $34.1 million, with a median of $34.0 million recorded in 2021.
  • Peak YoY movement for Long-Term Deferred Tax: plummeted 30.33% in 2022, then surged 95.05% in 2023.
  • A 5-year view of Long-Term Deferred Tax shows it stood at $23.7 million in 2021, then fell by 20.94% to $18.7 million in 2022, then soared by 95.05% to $36.5 million in 2023, then rose by 25.83% to $46.0 million in 2024, then grew by 14.76% to $52.8 million in 2025.
  • Per Business Quant, the three most recent readings for CPRX's Long-Term Deferred Tax are $52.8 million (Q4 2025), $48.3 million (Q3 2025), and $50.7 million (Q2 2025).